OrthoPediatrics (OrthoPediatrics) ROCE % : -9.87% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is OrthoPediatrics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OrthoPediatrics's annualized ROCE % for the quarter that ended in Mar. 2024 was -9.87%.

OrthoPediatrics ROCE % Historical Data

The historical data trend for OrthoPediatrics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrthoPediatrics ROCE % Chart

OrthoPediatrics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-6.74

-13.33

-6.38

-6.49

OrthoPediatrics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-8.72	-3.06	-3.84	-11.73	-9.87

OrthoPediatrics ROCE % Calculation

OrthoPediatrics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-25.766	/	( ( (427.727 - 30.871)	+	(438.745 - 41.666) )	/ 2 )
	=	-25.766	/	( (396.856	+	397.079)	/ 2 )
	=	-25.766	/	396.9675
	=	-6.49 %

OrthoPediatrics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-38.892	/	( ( (438.745 - 41.666)	+	(437.185 - 45.82) )	/ 2 )
	=	-38.892	/	( ( 397.079	+	391.365 )	/ 2 )
	=	-38.892	/	394.222
	=	-9.87 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

OrthoPediatrics (NAS:KIDS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OrthoPediatrics ROCE % Related Terms

Thank you for viewing the detailed overview of OrthoPediatrics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OrthoPediatrics (OrthoPediatrics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrthoPediatrics Corp (NAS:KIDS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2X7:Germany

Address

2850 Frontier Drive, Warsaw, IN, USA, 46582

Website

https://www.orthopediatrics.com

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.

Executives

Terry D Schlotterback	director	2850 FRONTIER DRIVE, WARSAW IN 46582
Fred Hite	director, officer: Chief Financial Officer	ORTHOPEDIATRICS, 2850 FRONTIER DR., WARSAW IN 46582
Dyer George Sinclair Mitchell	director	55 ORCHARD ST., CAMBRIDGE MA 02140
Gregory A Odle	officer: Executive Vice President	2850 FRONTIER DRIVE, WARSAW IN 46582
Joseph W Hauser	officer: Sr VP & GM Trauma & Deformity	6428 RIDGELINE DR, HUDSON OH 44236
Jimmy Duane Mcdonald	director	28662 N. 71ST STREET, SCOTTSDALE AZ 85226
David R Pelizzon	director, 10 percent owner	2850 FRONTIER DR, WARSAW IN 46582
Squadron Capital Holdings Llc	10 percent owner	18 HARTFORD AVENUE, PO BOX 223, GRANBY CT 06053
Squadron Capital Llc	10 percent owner	2850 FRONTIER DR., WARSAW IN 46582
Harold Ruf	director	2850 FRONTIER DR, WARSAW IN 46582
Jennifer N. Pritzker	10 percent owner	C/O SQUADRON CAPITAL LLC, 104 S. MICHIGAN AVENUE, SUITE 500, CHICAGO IL 60603
Infante (reynolds) Marie C	director	2850 FRONTIER DR, WARSAW IN 46582
Stephen F Burns	director	2850 FRONTIER DRIVE, WARSAW IN 46582
Berry Bernie B Iii	director	2850 FRONTIER DRIVE, WARSAW IN 46582
Mark C Throdahl	director, officer: President and CEO	ORTHOPEDIATRICS, 2850 FRONTER DR., WARSAW IN 46582